Atomera (ATOM) Q4 2023 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2023 earnings summary
6 Nov, 2026Executive summary
MST targets a cited $550B semiconductor market through an IP licensing model, with fees and royalties tied to customer progression through integration, installation, qualification, and production.
The pipeline included 20 customers and 26 engagements, with activity covering 10 of the top 20 semiconductor makers and 50% of the world’s top semiconductor makers.
MST was installed at two customer fabs; additional engagements are progressing toward royalty-based manufacturing and distribution licenses.
Financial highlights
FY 2023 revenue was $550K, up from $382K in FY 2022; gross profit was $522K, operating expenses were $21.199M, and operating loss was $20.677M.
FY 2023 net loss was $19.790M and adjusted EBITDA loss was $16.587M, compared with $17.4M and $14.1M, respectively, in FY 2022.
Q4 2023 revenue was $550K, versus $0 in Q4 2022, from milestones tied to MST installation at a licensee; net loss was $4.580M and adjusted EBITDA loss was $3.8M.
Outlook and guidance
The productization roadmap spans silicon validation, process qualification, and volume production after MST installation, wafer manufacturing, process-design-kit freeze, and chip design.
Management is focused on advancing additional customer engagements toward royalty-based manufacturing and distribution licenses.
Stated technology focus areas include advanced nodes, RF-SOI, DRAM, and MST-SP/SPX.
Latest events from Atomera
- MST advanced through customer evaluation, but commercial adoption and revenue remained unproven.ATOM
Q4 2016 - MST evaluations expanded, but commercialization remained unproven amid losses and cash burn.ATOM
Q4 2017 - Initial licenses marked progress, but commercialization remains gated by qualification and cash burn.ATOM
Q4 2018 - Revenue grew, but losses and commercialization hurdles remained substantial.ATOM
Q4 2019 - Cash rose to $37.9 million as a paid manufacturing JDA advanced MST toward commercialization.ATOM
Q4 2020 - JDA milestones and foundry evaluation expanded prospects, but commercialization remained unproven amid $15.7M losses.ATOM
Q4 2021 - Customer milestones advanced, but commercial royalties remain unproven amid continued losses.ATOM
Q4 2022 - Q3 revenue was $0 as GAA, memory and IQE-led GaN programs advanced.ATOM
Q3 2026 - Q2 2026 saw a $6.3M net loss, $158K revenue, and major MST milestones in RF and memory.ATOM
Q2 2026